Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
about
Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studiesManagement of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary FibrosisBeyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateOutcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature reviewNew insights into the impact of neuro-inflammation in rheumatoid arthritisAdvances in the treatment of rheumatoid arthritis.Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic DrugsWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Viral hepatitis screening guideline before biological drug use in rheumatic patients2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeTreatment of Bullous Systemic Lupus ErythematosusValidity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis.Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting.Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report.Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target.Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis.Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort studyMalignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.Evaluation of humoral and cellular immune responses to a DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats.The challenging interplay between rheumatoid arthritis, ageing and comorbidities.Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis.Green Tea Epigallocatechin-3-Gallate Suppresses Autoimmune Arthritis Through Indoleamine-2,3-Dioxygenase Expressing Dendritic Cells and the Nuclear Factor, Erythroid 2-Like 2 Antioxidant Pathway.Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.Ocular Tuberculosis--A Clinical ConundrumPrimary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumabTuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritisCombined Expression of IFN-γ, IL-17, and IL-4 mRNA by Recall PBMCs Moderately Discriminates Active Tuberculosis from Latent Mycobacterium tuberculosis Infection in Patients with Miscellaneous Inflammatory Underlying ConditionsCancer and autoimmunity: Harnessing longitudinal cohorts to probe the link.Safety and immunogenicity of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats.Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population.Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations.Adverse reactions to biologic agents and their medical management.Vaccination of patients with autoimmune inflammatory rheumatic diseases.Safety issues and concerns of new immunomodulators in rheumatology.
P2860
Q26772850-D401F23B-B589-4FD7-B700-BE2D8F7993DDQ26781712-9E07BC6E-5DC4-4E3C-8A2B-5748A3A44B32Q26782993-939D6BD5-942A-4093-BAF9-21A993620E48Q26859134-5E24854E-C58A-4B46-A0F5-C831563E2329Q26995202-7552EB95-D437-4212-A0BF-215075A215A4Q27023946-F1C7050B-8123-430D-8A74-C1E503E6989BQ27691822-24E750DE-D42B-41E5-9EE7-BCB8C7BCF8D5Q28073436-62A1D7DF-680F-4F8E-994B-FF3C98A36385Q28074148-E381FDE6-AB5A-46C4-8A60-B0785CD9F1C8Q28076767-67A9DA95-D0A5-4B36-8598-7182C91D94A2Q28081356-3093DCF2-1120-4860-867F-D21E669BC0B0Q28087628-D2B79762-34B8-4BDA-BC66-B519464402D2Q31122982-C11A4797-8BD9-4E58-9BA3-046FB369448CQ33730446-9E8962DC-5FB2-4DE6-8397-71760A2BDD81Q33734256-7F03E228-D61E-4766-AEB9-036BEC7E6A32Q33778719-5E37DD97-6CFF-41AF-8141-D47282CA7BD8Q34493588-5959B677-028F-49B9-97BA-E1332EA89212Q35084199-1E3C1BDB-44D8-49F8-97C7-B311B632D056Q35204309-05E50AE7-BD44-4327-8A87-DEA8EEDA8346Q35622999-C4BFEBE7-13DE-4A9A-A2F0-9190C7AC97B5Q35673147-460D3DBE-6560-41A1-B6E5-79D9BAC5E54EQ35813092-2ED8C2A6-D832-4BF9-BB2D-09493F35FB31Q35842876-8DB4A6A9-73F5-4ADF-8C4B-22D99F47B98AQ35887085-649C769B-0E93-4020-A832-AEF49F2F76C2Q36000249-8801D58B-3931-4935-B014-F577F75BABA5Q36036975-107EC8A5-5E98-4522-99B0-DE6DD27BC782Q36062141-171ACC6F-7B6C-4F4A-9D60-77E62EAF051BQ36300479-5FD330D0-D6B5-4393-9006-CDC13756B5EFQ36599330-A07AEB93-B8C5-417D-827C-F4313F8659D6Q36714237-B7E68CBC-ADE6-4B91-90BA-AFD30EEDDF3DQ36968737-42298672-DB28-4088-839E-0A525C86B39BQ36999711-5F80B9B1-687E-48BF-A2C7-FDBCB1144073Q37100264-BD70F709-17FE-4CE3-9D96-5B20D642E8C7Q37320179-BC1BF649-5E95-4149-B02A-AD4BA74059EDQ37627252-69293CD0-2A5A-4F9A-89E9-9F04E08713F8Q38176549-833D4CFE-E5B9-4A96-852F-D1873EC98059Q38211695-B4CF14F4-27E5-4B85-A3EA-F899325256C5Q38238948-DFF6674B-AFB1-49E1-BEF9-C496E260A40EQ38285275-BFEA99AA-A051-4BDD-97CC-2F60BC2EC2C2Q38292111-64302F3F-76A1-4511-8BA7-82B437A389CE
P2860
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@en
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@en-gb
type
label
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@en
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@en-gb
prefLabel
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@en
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@en-gb
P2093
P2860
P50
P1476
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@en
P2093
Cécile Gaujoux-Viala
Jackie L Nam
Kevin Winthrop
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-204575
P407
P50
P577
2014-01-08T00:00:00Z